IRIDEX Corporation IRIX

Despite a 7% revenue dip from retina headwinds, IRIDEX Corp (IRIX) posts record glaucoma probe volume and reaffirms full-year guidance.

Moby summary of IRIDEX Corporation's Q2 2026 earnings call

MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026. Second Quarter 2026 Financial Highlights Generated total revenue of $12.6 million, compared to $13.6 million in the prior year periodCyclo G6® product family reven

MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026. The Company’s management team will host a corresponding conference call beginning a

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company’s line of EndoProbe® Handpieces. Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Hand

IRIDEX Corp (IRIX) reports a milestone in profitability and strategic partnerships amid international headwinds and supply chain challenges.

2026 Guidance AffirmedMOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights Generated total revenue of $11.8 million, compared to $11.9 million in the prior year periodCyclo

MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026. The Company’s management team will host a corresponding conference call beginning at 2:0

MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States. Through this partnership,

Moby summary of IRIDEX Corporation's Q4 2025 earnings call